At ASCO, researchers presented on the WINTHER trial, which despite setbacks showed that both DNA and RNA analysis can be used to guide personalized treatment strategies.
Researchers found that some molecularly defined subsets of patients responded to targeted drugs while others didn't.
The institutes will explore the use of Inivata's liquid biopsy platform to analyze ctDNA to measure minimal residual disease in NSCLC patients.
Diagnostic WGS will be centralized and performed at the same Genomics England facility used in the 100,000 Genomes Project.
The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
Using a protocol developed at the University of Oxford, the researchers hope that nanopore sequencing can aid diagnosis and drug resistance profiling in remote areas.
Researchers found that functional assays could improve the classification of cystic fibrosis-related missense variants with variable disease expressivity.
The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.
The projects, organized by Friends of Cancer Research in the US and the Quality Assurance Initiative Pathology (QuIP) in Germany, are comparing different TMB assays.
The study demonstrates that Veracyte's new test improves upon an earlier version in its ability to identify thyroid nodules that are likely to be benign.
The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.
The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
CMS will reimburse FoundationOne CDx at a rate of $3,500 per test for a nine-month period starting July 1.
The group will combine VIB's sequencing technology with Verge's machine learning platform to study banked tissue samples at UCSD in a drug discovery effort.
Under a collaboration with GeneDx, Boston Children's has rapidly sequenced the exomes of 20 NICU babies and have arrived at a likely diagnosis in around 85 percent.
The team came up with an algorithm called bloodTyper for antigen-typing based on whole-genome sequences.
The project seeks to understand how genome sequencing as a first-line diagnostic in infants with likely hereditary disorders can impact long-term health outcomes.
A new analysis says sequencing early in in the diagnostic process for infants with suspected Mendelian disorders is cost-effective.
Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.